Cargando…

1134. Lenzilumab Treatment in COVID-19 Pneumonia Reduces Circulating Cytokines and Markers of Systemic Inflammation

BACKGROUND: Coronavirus disease 2019 (COVID-19) results from SARS-CoV-2-induced hyperinflammatory immune response, orchestrated by granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF increases interleukin-6 (IL-6) levels, ultimately leading to increased C-reactive protein (CRP). The LI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chappell, Dale, Kilcoyne, Adrian, Cerasoli, Frank, Lukas, John, Durrant, Cameron, Temesgen, Zelalem, Polk, Christopher, Baker, Jason, Marconi, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752421/ http://dx.doi.org/10.1093/ofid/ofac492.973

Ejemplares similares

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial
por: Temesgen, Zelalem, et al.
Publicado: (2023)

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
por: Temesgen, Zelalem, et al.
Publicado: (2022)

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
por: TEMESGEN, ZELALEM, et al.
Publicado: (2021)

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
por: Temesgen, Zelalem, et al.
Publicado: (2021)

40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial
por: Temesgem, Zelalem, et al.
Publicado: (2021)

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
por: Temesgen, Zelalem, et al.
Publicado: (2020)

In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Temesgen, Zelalem, et al.
Publicado: (2021)

P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL
por: Ross, David, et al.
Publicado: (2023)

Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England
por: Kilcoyne, Adrian, et al.
Publicado: (2022)

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

1134 Characteristics of Hospital-Acquired Influenza in Adults in Southern Ontario, 2005-2012
por: Vaisman, Alon, et al.
Publicado: (2014)

1134. Substance Use Disorder Patients’ Perspectives of a Multidisciplinary Antimicrobial Infusion Service
por: Juskowich, Joy J, et al.
Publicado: (2020)

1134. The Effect of Telehealth Antimicrobial Stewardship Program on Antimicrobial Use in a Pediatric Intensive Care Unit
por: Alghounaim, Mohammad, et al.
Publicado: (2021)

Vacuum tests in Ring 2 (56.4 A), Run 1134 MD, 12th June 1980
por: Hilleret, Noël, et al.
Publicado: (1980)

1134. Antibiotic Indications and Appropriateness in the Pediatric Intensive Care Unit: A 10 Center Point Prevalence Study
por: Chiotos, Kathleen, et al.
Publicado: (2019)

Correction: Vargas et al. Solving Schrödinger Bridges via Maximum Likelihood. Entropy 2021, 23, 1134
por: Vargas, Francisco, et al.
Publicado: (2023)

1134. Novel T2Candida Panel Assay Compared With Blood Cultures for Detection of Candidemia in Transplant and Non-Transplant Patients
por: Hussain, Noman, et al.
Publicado: (2018)

Changes in microbial community and enzyme activity in soil under continuous pepper cropping in response to Trichoderma hamatum MHT1134 application
por: Mao, Tingting, et al.
Publicado: (2021)

P1134: OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA POST-CBTK INHIBITOR THERAPY IN THE UNITED STATES AND JAPAN: A STUDY OF TWO REAL-WORLD DATABASES
por: Rai, S., et al.
Publicado: (2022)

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
por: Shah, Nirav, et al.
Publicado: (2023)

Relevant Cytokines in the Management of Community-Acquired Pneumonia
por: Rendon, Adrian, et al.
Publicado: (2016)

Introduction to the Symposium on Antimicrobial Therapy
por: Temesgen, Zelalem
Publicado: (2011)

Surveillance of vancomycin-resistant enterococci reveals shift in dominating clones and national spread of a vancomycin-variable vanA Enterococcus faecium ST1421-CT1134 clone, Denmark, 2015 to March 2019
por: Hammerum, Anette M, et al.
Publicado: (2019)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Mind the gap: Time to address implementation gaps in tuberculosis diagnosis and treatment
por: Pai, Madhukar, et al.
Publicado: (2016)

Quality: The missing ingredient in TB care and control
por: Pai, Madhukar, et al.
Publicado: (2018)

The calendar of cytokines: Seasonal variation of circulating cytokines in chronic venous insufficiency
por: Spath, Paolo, et al.
Publicado: (2017)

Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients
por: Dessie, Zelalem G., et al.
Publicado: (2021)

Crystal structures of two copper(I)–6,6′-dimethyl-2,2′-bipyridyl (dmbpy) compounds, [Cu(dmbpy)(2)](2)[MF(6)]·xH(2)O (M = Zr, Hf; x = 1.134, 0.671)
por: Wang, Yiran, et al.
Publicado: (2021)

Serum Cytokines and FeNO in School-Aged Children with Mycoplasma pneumoniae Pneumonia
por: Jin, Hai-li, et al.
Publicado: (2020)

Cytokine signatures associate with disease severity in children with Mycoplasma pneumoniae pneumonia
por: Yang, Mingyue, et al.
Publicado: (2019)

Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19
por: Kahn, Robin, et al.
Publicado: (2020)

The Bronchial Circulation in COVID-19 Pneumonia
por: Ackermann, Maximilian, et al.
Publicado: (2021)

Calming the Cytokine Storm in Pneumonia by Biomimetic Nanoparticles
por: Xia, Yuqiong, et al.
Publicado: (2020)

The Biphasic Phenomenon of Cytokine Storm in COVID Pneumonia
por: Shah, Nehal M., et al.
Publicado: (2022)

Human–wildlife conflict in the surrounding districts of Alage College, Central Rift Valley of Ethiopia
por: Temesgen, Zelalem, et al.
Publicado: (2022)

The spatial modification effect of predictors on household level food insecurity in Ethiopia
por: Dessie, Zelalem G., et al.
Publicado: (2022)

Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest
por: Mondet, Julie, et al.
Publicado: (2015)

Increased Expression of Circulating Stress Markers, Inflammatory Cytokines and Decreased Antioxidant Level in Diabetic Nephropathy
por: Mansoor, Ghazal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2re7mnu41et3vigm354d8da1m6